cfDNA bisulfite sequencing of 239 breast cancer and 278 healthy subjects

Breast cancer causes the most cancer-related death in women and is the costliest cancer in the US for medical service and prescription drug expenses. Breast cancer screening is recommended by different health authorities in the US; however, current screening methods often have high false positive rates. Liquid biopsy based on circulating tumor DNA (ctDNA) has emerged as a potential approach to screen for cancer. However, the detection of breast cancer, particularly in early stages, faces challenges due to the low amount of ctDNA and heterogeneity of molecular subtypes. Here, we employed a multimodal approach, namely SPOT-MAS, to simultaneously analyze multiple signatures of cell free DNA in plasma samples of 239 breast cancer patients and 278 healthy subjects.